75894-93-8

Basic information

• Product Name: 2-(3,5-DIBROMOPHENYL)ETHANOL
• Synonyms: 2-(3,5-DIBROMOPHENYL)ETHANOL
• CAS NO: 75894-93-8
• Molecular Formula: C₈H₈Br₂O
• Molecular Weight: 279.96
• Mol File: 75894-93-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3,5-DIBROMOPHENYL)ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-DIBROMOPHENYL)ETHANOL(75894-93-8)
• EPA Substance Registry System: 2-(3,5-DIBROMOPHENYL)ETHANOL(75894-93-8)

Safety Data

• Hazardous Substances Data: 75894-93-8(Hazardous Substances Data)

Usage

Class

Phenylethanols (characterized by a phenol group attached to an ethane chain)

Usage

Intermediate in the synthesis of pharmaceuticals and agrochemicals, production of various industrial chemicals

Physical form

White to off-white solid

Melting point

Around 69-71°C

Boiling point

Around 310-312°C

Biological activity

Exhibits some biological activity, making it a subject of interest in medicinal chemistry and drug development

Upstream product

• 184769-87-7 3,5-dibromo-4-aminophenethyl alcohol 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 188347-49-1 2-(3,5-dibromophenyl)acetic acid 
• 626-39-1 1,3,5-trisbromobenzene 
• 75-21-8 oxirane 

Downstream Products

• 18226-46-5 1,3,5-tris(2-chloroethyl)benzene 
• 476195-64-9 C₆₆H₉₆O₅Si₃ 
• 476195-63-8 C₆₄H₉₆O₃Si₃ 
• 1027302-33-5 C₅₆H₇₈Br₂O₅Si 
• 476195-65-0 {2-[3,5-bis-(3-dodecyloxy-5-ethynyl-phenylethynyl)-phenyl]-ethoxy}-tert-butyl-dimethyl-silane 

Relevant articles and documents

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties

The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody-drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD4 levels. These experiments culminate with the identification of one degrader conjugate, which exhibits antigen-dependent antiproliferation effects in LNCaP prostate cancer cells.

Synthesis of 1,3,5-tris(2-chloroethyl)- and 1,3,5-tris(2-iodoethyl)benzenes

A new method has been elaborated for the synthesis of 1,3,5-tris(2-chloroethyl)- and 1,3,5-tris(2-iodoethyl)benzenes based on the commercially available 1,3,5-tribromobenzene.

4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES

The present invention relates to a compounds of formula I wherein R1, R1′, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.